Alcon Announces U.S. Launch of TRYPTYR (acoltremon ophthalmic solution) 0.003%, a New Prescription Treatment Option for Millions of Dry Eye Sufferers

Alcon has announced the U.S. commercial availability of TRYPTYR® (acoltremon ophthalmic solution) 0.003%, the latest innovation for the treatment of the signs and symptoms of Dry Eye Disease (DED).¹ Approved by the U.S. Food and Drug Administration (FDA) in May, eye care professionals (ECPs) across the U.S. can officially begin prescribing TRYPTYR to their  patients, expanding their DED treatment options for the more than 30 million Americans suffering with dry eye symptoms.¹¹ 

“TRYPTYR is highly anticipated in the dry eye disease treatment space as the first neuromodulator eye drop to rapidly increase natural tear production, as early as day one,” said Lisa Praeger, Vice President, General Manager, U.S. Ocular Health Pharmaceutical, Alcon. “As the global eye care leader with a comprehensive portfolio of dry eye products—from over-the-counter offerings to prescription therapies—Alcon is uniquely positioned to deliver this innovation to eye care professionals and the millions of patients who need dry eye disease relief. Leveraging our deep commercial expertise and specialized sales force, we’re excited to give broader access to this important new treatment option.” 

Many commonly used DED treatment options have limitations, including slow onset. Among  surveyed dry eye patients, only 13% felt their dry eye was well managed.^4-10* A first-in-class TRPM8 receptor agonist (neuromodulator), TRYPTYR demonstrated statistically significant increase in natural tear production as early as Day 1.^2,3 

“Understanding patients’ dry eye disease struggles allow us to make informed  recommendations on how to best manage their symptoms and create an effective ongoing disease  management plan,” said Paul Karpecki, OD, Director of Corneal Services and the Advanced OSD Clinic in Lexington, Kentucky. “TRYPTYR represents an important innovation—its fast onset and novel mechanism provide a new option to millions of dry eye patients.”

Committed to supporting ECPs with innovative products and educational resources, Alcon and its team of dedicated dry eye sales specialists have also launched an ECP campaign focusing on the speed of rapid natural tear production with TRYPTYR. The campaign features ECP tools, including videos and an interactive website along with a patient website. Additionally, Alcon recently hosted a national broadcast event for ECPs, featuring in-depth conversations surrounding this DED treatment option.  

“TRYPTYR is an important milestone in the treatment of dry eye disease, and I’m equally  encouraged by Alcon’s commitment to supporting eye care as we continue to address the signs and  symptoms of dry eye disease for our patients,” said Preeya K. Gupta, MD, Triangle Eye Consultants in Raleigh, North Carolina. “Alcon is not only expanding the dry eye treatment options, but they are also supporting clinicians with the educational resources needed to confidently integrate new treatments like TRYPTYR into our practices.”  

The U.S. launch will also coincide with expansive access initiatives, including a full Field Access Management team dedicated to assisting ECPs with fulfillment, and a First Fill Free trial program for eligible TRYPTYR patients. Additionally, ongoing copay support will be offered for refills for eligible  patients.  

ECPs interested in more information on TRYPTYR may click here.

INDICATIONS AND USAGE 

TRYPTYR (acoltremon ophthalmic solution) 0.003% is indicated for the treatment of the signs and  symptoms of dry eye disease (DED).^t

IMPORTANT SAFETY INFORMATION 

Warnings and Precautions 

Potential for Eye Injury and Contamination: To avoid the potential for eye injury and  contamination, advise patients not to touch the vial tip to the eye or other surfaces. 

Use with Contact Lenses: TRYPTYR should not be administered while wearing contact lenses. If  contact lenses are worn, they should be removed prior to administration of the solution. Lenses  may be reinserted 15 minutes following administration of TRYPTYR. 

Adverse Reactions 

In clinical trials, the most common adverse reaction was instillation site pain (50%). Please click here for the TRYPTYR Full Prescribing Information. 

References  

1. 2023 Dry Eye Products Markets Report, Market Scope, 2023. 
2. TRYPTYR US FDA Prescribing Information. 2025.  
3. Data on File for COMET-2 Phase 3 Study. Alcon 2025. 
4. Data on File for COMET-3 Phase 3 Study. Alcon 2025. 
5. Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology. 2007;114(1):76-79. doi: 10.1016/j.ophtha.2006.05.077. 
6. Semba CP, Gadek TR. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease. Clin Ophthalmol. 2016;10:1083-1094. doi: 10.2147/OPTH.S110557. 
7. Restasis. Prescribing Information. Allergan; 2012. Accessed July 8, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050790s020lbl.pdf. 
8. Hovanesian JA, Nichols KK, Jackson M, et al. Real-world experience with lifitegrast ophthalmic solution (Xiidra®) in the U.S. and Canada: retrospective study of patient characteristics, treatment patterns, and clinical effectiveness in 600 patients with dry eye disease. Clin Ophthalmol. 2021;15:1041-1054. doi: 10.2147/OPTH.S296510. 
9. Cook N, Mullins A, Gautam R, et al. Evaluating patient experiences in dry eye disease through social media listening research. Ophthalmol Ther. 2019;8(3):407-420. doi: 10.1007/s40123-019-0188. 
10. Mbagwu M, LaPrise A, Harris J, Nair AA, Fain J, Harrison DJ. Characterization of discontinuation and switching patterns of dry eye disease medications using linked EHR registry and claims data. Presented at: American Society for Cataract and Refractive Surgery Conference; April 5-6, 2024; Boston, MA.  

Read more news from WO here.